Presentation by Dr. Pengda Liu. Pengda obtained his bachelor's degree in Hefei University of Technology in Bioengineering. He joined Dr. John Stiller's lab in the Biology Department at ECU and graduated with a Ph.D. degree in IDPBS program in Dec. 2008. Afterwards, he did a short postdoc with Dr. Arno Greenleaf, who is also on Pengda's Ph.D. thesis committee at Duke University Medical Center and later joined Dr. Wenyi Wei's lab at Beth Israel Deaconess Medical Center at Harvard Medical School. Pengda was promoted to instructor at Harvard Medical School in 2013 and initiated his independent lab at UNC-Chapel Hill in March 2016. With John at ECU and Arno at Duke, Pengda identified key molecular features for RNA polII CTD and mammalian CDK12 as a novel CTD kinase. With Wenyi in Boston, Pengda discovered novel regulations and functions for the mTOR/Akt signaling. Pengda has published 24 research articles and 17 review articles, including first-author papers in Nature, Nature Cell Biology, Cancer Discovery, Molecular Cell, Genes and Development, Molecular Biology and Evolution and others. Pengda has obtained external funding and recognition as well, including a National Cancer Institute Pathway to Independence award, 40 under 40 award from ECU, IBM junior faculty development award and Atomwise AIM award. The major research focus for Pengda is to understand how dysregulation of the mTOR/Akt signaling contributes to tumorigenesis, and how we can target these discoveries for targeted therapy.
Thursday, January 25, 2018 at 4:00pm to 5:00pm
Bate Building, 1032
Greenville, NC 27858-4353